Drug Trial Radar · NCT05653037
A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 21, 2023
Primary completion
Oct 1, 2024
Study completion Nov 10, 2025
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects. The study will be performed in single ascending dose (SAD) phase in healthy subjects. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information and PK/PD data in each cohort. RBD4059, a GalNAc conjugated siRNA, is an FXI-targeted new molecular entity independently developed by Ribo using its proprietary siRNA delivery system - RIBO-GalSTARTM.
Conditions
- Healthy Volunteers
Interventions
RBD4059Drug
Subcutaneously Administered RBD4059 in Healthy Subjects.
PlaceboDrug
Subcutaneously Administered Placebo in Healthys Subject.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0Time frame: SAD: Up to Day 169 ;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Limited
Brisbane, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.